Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets ... Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. Show more
WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative...
WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4601 | -9.52568269808 | 4.8301 | 5.84 | 4.36 | 72468 | 5.07018308 | CS |
4 | 0.82 | 23.0985915493 | 3.55 | 12.89 | 2.95 | 2266067 | 8.88910656 | CS |
12 | -2.37 | -35.1632047478 | 6.74 | 12.89 | 2.95 | 716587 | 8.74036469 | CS |
26 | 1.346 | 44.5105820106 | 3.024 | 23.01 | 2.098 | 1359835 | 7.50110307 | CS |
52 | -19.43 | -81.6386554622 | 23.8 | 25.6 | 2.098 | 879870 | 7.04250234 | CS |
156 | -212.83 | -97.9880294659 | 217.2 | 239.8 | 2.098 | 311470 | 12.65660536 | CS |
260 | -745.63 | -99.4173333333 | 750 | 899.526 | 2.098 | 248615 | 26.80076171 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales